Stay updated with breaking news from Nasdaq Nrix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) released its earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.16, MarketWatch Earnings reports. Nurix Therapeutics had a negative net margin of 258.37% and a negative return on equity of 53.36%. The company had […]
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Inventiva (NASDAQ:IVA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Institutional and Insider Ownership 90.4% of Nurix Therapeutics […]
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Nurix Therapeutics in a research note issued to investors on Friday, September 8th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.86) per share for the […]
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) insider Gwenn Hansen sold 1,884 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $9.65, for a total value of $18,180.60. Following the transaction, the insider now owns 29,955 shares of the company’s stock, […]
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective […]